Polycystic Ovary Syndrome (PCOS) Renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS)

A global consensus process, culminating in a paper published in The Lancet in June, has led to the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex nature, which involves insulin resistance and long-term cardiovascular risk, rather than solely focusing on ovarian cysts, which are not a consistent marker.